This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Y-mAbs Therapeutics’s 8K filing here.
Y-mAbs Therapeutics Company Profile
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
Featured Articles
- Five stocks we like better than Y-mAbs Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
- Transportation Stocks Investing
- 3 EV Stocks Offering Unique Alternatives to Tesla
- Best Aerospace Stocks Investing
- 3 Stocks Leveraging NVIDIA’s Strength for Profits
